HIPAA compliance: the clock is ticking
09 May, 2002 by Cara GarretsonWith the first deadline to implement new medical record regulations less than a year away, bioscience companies should be taking a hard look at whether these complicated US federal mandates will affect them.
MBAs told to go offshore for biotech experience
08 May, 2002 by Daniella GoldbergBusiness management students were told yesterday that they may have to work overseas before they sought employment in Australia's biotechnology industry.
Research consortium seeks government support
08 May, 2002 by Tanya HollisA consortium of eight research groups is pitching for Victorian Government support in a bid to become Australia's first fee-for-service pharmaceutical pipeline group.
Vic Budget brings in the bucks for biotech
08 May, 2002 by Tanya HollisVictoria's government has unveiled a cash injection of $68.7 million for biotechnology and commercialisation, including a doubling in funding for medical research infrastructure in a bid to lure top scientists back to the state.
Tech CEOs tip biotech growth
07 May, 2002 by Daniella GoldbergCEOs of Australia's leading technology companies believe that the biotechnology and internet security sectors have the greatest potential for growth in the next 12 months, according to a Deloitte industry survey.
Hawke steps down from Autogen board
07 May, 2002 by Tanya HollisFormer Prime Minister Bob Hawke has resigned as a director of Autogen's board, citing heavy business and personal commitments.
Bio-boards under fire
06 May, 2002 by Daniella GoldbergIn the last month, three of Australia's most experienced listed biotechs have endured roller coaster rides on the stock market, in the case of all three because of upheaval at the board level.
Award nominations open
06 May, 2002 by Iain ScottThe Ian Clunies Ross Memorial Foundation has called for nominations for its 2003 National Science and Technology Award.
Health dept suspends clinical director
02 May, 2002 by Daniella GoldbergDr Bruce Hall, the clinical director in medicine at Liverpool Hospital, has been suspended by the New South Wales Health Department.
Kwik fix to avert disaster
30 April, 2002 by Daniella GoldbergJust over a month ago, with his company on the verge of big new international deals, Peptech managing director Stephen Kwik agreed to leave the company so the board could replace him with a CEO with scientific background and commercial expertise.
Compumedics buys US company, eyes Nasdaq
29 April, 2002 by Tanya HollisDeveloper of sleep disorders devices Compumedics has completed its first acquisition with the $US4 million purchase of Texas-based neurological instruments business Neuroscan.
Universities face review
29 April, 2002 by Daniella GoldbergNon-productive research, inflated course offerings, and inefficient bureaucrats in the higher education sector are some of the issues to be addressed in the first of a series of reviews of higher education by the Federal government.
Forum series threatened by lack of speakers
29 April, 2002 by Tanya HollisThe success of a Victorian government gene technology and biotech forum series was under threat because of a dearth of willing expert speakers, according to the Department of Human Services (DHS).
Biotech in Queensland: beautiful one day, smart the next
29 April, 2002 by Pete YoungQueensland is cooking up a thriving biotech sector by successfully blending half a dozen hard-to-find ingredients.
UNSW calls in heavyweights over allegations
26 April, 2002 by Daniella GoldbergOngoing investigations into the alleged misconduct of a University of New South Wales scientist, Prof Bruce Hall, are to be directed by a selection panel comprised of eminent scientist Sir Gustav Nossal and UNSW chancellor Dr John Yu and vice-chancellor Prof John Niland.
